In 2008, over 600 delegates from 16 countries attended and we arranged over 1,000 partnering meetings. For 2009, ERBI continues this successful format of bringing together industry experts from major pharmaceutical companies, international investors and biotech entrepreneurs with three main conference elements; the conference programme, formal partnering and the Technology Showcase.
This year amongst others, we will welcome:
Confirmed Keynotes:
• Dr Patrick Vallance, Senior Vice President, Drug Discovery, GSK
• Dr Andrew Dillon, CEO, NICE
Confirmed Speakers:
• Dr David Mott, General Partner, Biopharmaceutical Investments, New Enterprise Associates, USA
• Dr Margaret Beer, Senior Director and Head, Licensing and External Research, Europe, Merck Sharp & Dohme
• Dr Ruth Keir, Senior Director, SA Site Head Strategic Alliances, Pfizer Inc
• Dr Graeme Martin, President and CEO, Takeda Research Investment, Inc.
• Dr Ray Hill, ex Merck Sharp & Dohme
• Dr Barry Wilson, ex-Medtronic Inc
• Dr Mark Treherne, CEO, Senexis Ltd
• Dr Andy Richards, Enterpreneur
And Nigel Cameron, Illinois Institute of Technology who will be chairing a session entitled “Emerging Bio/medical Technologies”.
Registration is now open via the conference website, www.erbiconference.co.uk. To gain maximum exposure at this important event, you can also view the promotional opportunities and sponsorship packages on the website.
About ERBI
ERBI was established in 1997 with a three-year grant from the DTI. As a networking organisation for Cambridge and the East of England, our original goal was to provide opportunities for representatives from biotechnology and related companies to meet and interact. We achieved this by organising regular meetings and hosting an annual conference.
In 2000 ERBI became a self-financing, membership based company directed by a Board made up of representatives from the industry. Today we have over 360 members from all walks of the bio-community, and are recognised as Europe’s most successful regional bio-industry group. In January 2008 we incorporated the membership of the regional medical technology network, formerly known as Medilink East, to expand ERBI’s scope into medtech.
Since 2000 we have expanded our activities to cover many aspects of facilitating the growth of biotech in Cambridge and the East of England. The key objective underpinning our day to day work is to help our members become more competitive globally. Visit: www.erbi.co.uk
